A potential link between AQP3 and SLC14A1 gene expression level and clinical parameters of maintenance hemodialysis patients

Table 3 AQP3 and UT-B (SLC14A1) gene expression in study population with major coefficients comparison subdivisions

	*AQP3*		*UT-B (SLC14A1)*
	Me (25–75%)	P value	Me (25–75%)	P value
All patients	1.13 (0.73 – 1.49)	n/a	16.57 (15.34 – 17.18)	n/a
Sex	M: 1.13 (0.60 – 1.46)	0.45	M: 16.92 (15.60 – 17.16)	0.63
Sex	F: 1.09 (0.77 – 1.53)	0.45	F: 16.17 (15.15 – 17.45)	0.63
DM	Y: 1.39 (0.92 – 1.82)	0.13	Y: 16.95 (15.51 – 17.16)	0.58
DM	N: 1.11 (0.57 – 1.43)	0.13	N: 16.17 (15.27 – 17.19)	0.58
Treatment with ACEi or ARB	Y: 1.05 (0.76 – 1.43)	0.17	Y: 16.20 (15.15 – 17.11)	0.43
Treatment with ACEi or ARB	N: 1.21 (0.68 – 1.82)	0.17	N: 16.92 (15.70 – 17.45)	0.43
Residual kidney function	Y: 1.38 (0.64 – 1.68)	0.28	Y: 16.95 (16.09 – 17.47)	0.16
Residual kidney function	N: 1.10 (0.76 – 1.44)	0.28	N: 16.06 (15.15 – 17.14)	0.16
Cause of end-stage kidney disease	GN: 1.24 (0.88 – 1.50)	0.14	GN: 16.92 (15.92 – 17.19)	0.57
	AH: 1.07 (0.62 – 1.33)		AH: 15.88 (15.21 – 17.01)
	DM: 1.30 (0.92 – 1.82)		DM: 16.76 (15.15 – 17.00)
	Other: 0.84 (0.50 – 1.29)		Other: 16.99 (14.76 – 17.49)

Abbreviations: Me Median, n/a Non applicable, ACEi or ARB Angiotensin converting enzyme and receptor blockers, AH Arterial hypertension, DM Diabetes mellitus, F Females, GN Glomerulonephritis, M Males, N No, Y Yes

ISSN: 1471-2369